In this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts his experience serving on the FDA Oncologic Drugs Advisory Committee that reviewed and evaluated data from the POLARIX study and polatuzumab vedotin-piiq (Polivy)for patients with previously untreated LBCL.
